The Committee will discuss new drug application (NDA) 215244, for elamipretide hydrochloride injection, submitted by Stealth BioTherapeutics Inc., for the treatment of Barth Syndrome.
Similar Posts
Advancing Clinical Trial Participation for the LGBTQIA+ Community
Representatives of the FDA were fortunate to attend a community discussion on advancing clinical trial diversity for sexual and gender minority communities to help improve the generalizability of trial results across the entire population of patients who may use medical products.Direct Source Seafood LLC is Recalling Frozen Raw Shrimp Because Product May Have Become Contaminated with Cesium-137 (Cs-137)
December 19, 2025, Direct Source Seafood LLC, Bellevue, WA, is recalling approximately 83,800 bags of frozen raw shrimp, imported from Indonesia, sold under the Market 32 and Waterfront Bistro brands because they may have been prepared, packed, or held under insanitary conditions whereby they may haLaboratory Information Bulletins
Laboratory Information Bulletins available to the publicClinical Outcome Assessment (COA) Qualification Program: Frequently Asked Questions
CDER Clinical Outcome Assessments (COA) Qualification Program: Frequently Asked Questions (FAQs)Guidance Snapshot Pilot
Guidance Snapshots are a communication tool that provide highlights from the document using visuals and plain language. This pilot program is intended to increase awareness for FDA guidance documents to support the efficient application of the documents’ recommendations.Absolutely Natural – 715690 – 12/30/2025
CGMP/Finished Pharmaceuticals/Adulterated